$LSTA News

HC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances

Lisata Therapeutics shares are trading higher after the company entered into a definitive agreement to be acquired by Kuva Labs.

Lisata Therapeutics shares are trading higher after the company entered into a definitive agreement to be acquired by Kuva Labs.

Reported Friday, Lisata Therapeutics To Be Taken Private By Kuva Labs In A Deal Offering Stockholders $5.00 Per Share Plus A $1.00 Contingent Value Right Per Share

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

What Does the Market Think About Lisata Therapeutics Inc?

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Lisata Therapeutics shares are trading higher after the company announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical.

Lisata Therapeutics, Qilu Pharmaceutical Mutually Terminate 2021 License And Collaboration Agreement

How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook

Brookline Capital Downgrades Lisata Therapeutics to Hold

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Why Is Lisata Therapeutics Stock Gaining Today?

Lisata Therapeutics shares are trading higher after the company announced a binding term sheet to be acquired by Kuva Labs for $4.00 per share in an all-cash tender offer.

Trading Halt: Halt status updated at 7:20:00 AM ET: Quotation Resumption: News and Resumption Times

Lisata Therapeutics To Be Acquired By Kuva Labs In $4.00/Share Tender Offer

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

LSTA Releases Valuations Report on Level 3 Loans

Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ...